univers coverag
calendar event
reimburs review data releas payer edt
medic meet essenti protein engin summit american societi
cellular therapi american societi breast surgeon american geriatr societi
american associ immunologist american associ orthodontist
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
stannsoporfin hit roadblock fda adcom consist
bottom line today fda adcom vote approv stannsoporfin
treatment hyperbilirubinemia panel gener view phase
pivot stat sig small studi result inconsist support
studi addit bigger concern panel safeti given short-term safeti
signal phototox thrombocytopenia potenti long-term neurolog well
toxic signal relat liver brain neglig risk-adjust sale
model grow fda adopt adcom recommend
like could set back program year stannsoporfin delay
signific impact near-term earn estim impact ep
one first three key pipelin relat mileston year believ
add investor concern around abil execut pipelin diversifi away
acthar revis model follow earn next week might get addit color
manag plan next step
biggest concern panel limit long-term neurolog follow data
phase pivot studi statist signific panel saw overal efficaci data
short-term risk phototox thrombocytopenia remain concern
toxic signal relat liver brain panel get comfort
dcf valuat use discount rate lt growth rate
bottom line yesterday even adama report financi result first full quarter
gocovri launch sale exceed street-high estim
consensu mean compani indic number prescript
month march exceed number januari februari combin total number
distinct prescrib also nearli doubl end februari march adama report ep
quarter slightli better estim exit march
cash equival also earn releas adama provid updat
fda meet regard regulatori path lacosamid state fda agre
singl pivot phase studi includ head-to-head versu vimpat placebo arm
trial expect begin expect share react posit updat
continu believ adama offer attract long-term opportun substanti upsid
earlier clinic program show promis next year follow quarter updat
compani model sale forecast gocovri pd dyskinesia price target increas
maintain outperform rate
gocovri first full quarter launch adama exit prescript per week rate accord
estim
also earn releas confer call adama report posit feedback fda
meet clinic path lacosamid partial onset epilepsi
last month adama report two-year open label data eas studi show gocovri
effect dyskinesia symptom durabl week patient previous non-
respond amantadin ir see note data call question main bear thesi
sourc much skeptic long-term potenti gocovri parkinson dyskinesia confirm
gocovri differenti profil versu gener amantadin also suggest extend releas
formul interchang molecul
adama lack meaning catalyst could impact share price prior earn releas
base quarterli result manag disclosur updat compani model
forecast better reflect compani on-going oper
cordi woe unlik spread guid clear event pt
 methodolog ep
bottom line though result disappoint overal believ sever
aspect perform well overshadow cordi ultim believ
quarter guidanc clear event stock core pharma
busi anoth quarter strong perform revenu oper profit beat
consensu estim addit medic segment ex-cordi appear perform well
manag describ high demand at-hom navihealth solut
lower forward estim believ gener price continu stabil cordi
issu oper mean like fix believ patient recoveri
busi still perform well maintain op pt move
closer look cordi suggest issu fix
cordi woe like infect patient recoveri busi
piec medic segment perform well
pharma beat improv outlook overshadow
buy-sid perform better expect sell-sid pressur
adj dilut ep continu oper
revenu earn start year
bottom line announc good result even total revenu quarter
came ahead model due strong trubridg revenu adj ep also beat leerink
consensu estim howev book quarter declin y/i due part
weaker-than-expect trubridg book howev manag highlight
seen uptrend trubridg cross-sel last four quarter believ
ampl cross-sel opportun remain ad new commun hospit client
quarter character pipelin healthi despit face tough commun ehr market
relat revenu expect pick back custom seek becom
compliant januari overal impress good perform
quarter adjust estim quarter pt stand
trubridg remain growth engin support cross-sel success
book light quarter pipelin describ robust
market dynam continu shift long-term financ arrang
revenu present mm non-gaap report exclud acquir amort stock comp
expens transact cost
book steadi market remain highli competit
bottom line allscript deliv decent start year book line consensu
expect though revenu adjust ebitda adjust ep slightli behind
consensu expect guidanc re-affirm call manag highlight
sell well across busi line ei platform drive cross-sal
client base respond well practic fusion life scienc payer group
deliv good result quarter decent maintain mp rate
believ nearli top-lin growth acquir asset earn revenu
slightli behind expect believ end-market slow meaning
number breadth adjust also seem high pt stand maintain mp
solid start year
book sale activ differenti peer
transact show sign traction
quarter larg manag expect
healthgrid connect solut sound interest
revenu adjust non-gaap mm ep adjust street-compar basi ex
fa expens non-cash expens
use wacc termin growth rate
bottom line morn announc non-gaap ep line
consensu lp guidanc respect management reiter guidanc
although suggest potenti upsid recent approv exparel use nerv block
note increas earli interest recent volum growth addit continu traction
op collabor howev continu look greater visibl unbundl
discret payment j-code initi exparel sale expect high
end manag guidanc believ achiev given nerv block approv
well recent volum trend continu believ meaning upsid consensu estim
could come exparel reimburs get unbundl although likelihood remain unclear
reiter market perform rate maintain price target stock
remain high end manag guidanc recent volum trend continu
could see manag rais guidanc later year
exparel could receiv j-code earli like start jan howev
larger upsid opportun resid potenti unbundl
pacira continu push forward initi expand exparel use ambulatori set
continu leverag collabor
rais solid like enough derail lt growth
 methodolog sale
bottom line deliv anoth quarter out-performance come ahead
expect across key busi highlight strong underli believ
sustain omnipod adopt momentum also rais sale guidanc
midpoint line compani beat vs quarterli guidanc share under-perform
tomorrow reaction would recommend use weak entri point
believ long-term growth stori derail point instal
base grew high-teen base estim histor season weaker
quarter impact distributor inventori drawdown tie op
updat guidanc like prove conserv instal base momentum build
coverag secur medicare/medicaid formulari coverag
part plan place intern transit direct like prove better expect
execut perspect achiev sustain oper margin
profit also note histor er conserv side guidanc
last year also rais low end rang despit beat
prior year reiter guidanc despit deliv beat build foundat
sustain strong double-digit sale growth continu develop pipelin upcom
dash person diabet manag launch type product horizon ap artifici
pancrea come market next year
reiter op pt
outlook move higher still conserv intern transit biggest risk seem
appropri handicap guidanc
revenu ep figur includ fa option expens
 methodolog averag price-to-earnings p/ dcf methodolog
bottom line yesterday morn regeneron report mix result total revenu
miss consensu estim pro-forma ep
beat consensu miss estim reassuringli eylea beat consensu
estim us dupix kevzara praluent previous disclos partner sanofi fell
short consensu prior estim total revenu consensu
estim sanofi collabor revenu also came expect posit expens varianc
result better oper margin perform consensu model although
improv oper margin compar prior period expens guidanc reduc slightli
tax rate guidanc improv modestli well
revenu mm dilut ep non-gaap
recap eteplirsen paus ema pipelin base biz intact pt
bottom line sarepta hot streak hit mostli expect blip sale ep
result came weaker consensu eteplirsen progress ema like take
candid chanc re-examin eteplirsen ema newli forg partnership myonexu
buffer posit outlook delay eu launch assumpt eteplirsen golodirsen
casimersen accord latest develop reiter op rate new pt
previous reflect updat view
growth qoq buck typic headwind management remain laser-focus eu
despit neg trend vote
nda file on-track golodirsen exon skip-amen dmd essenc trial may serv dual
purpos confirmatori also seek approv casimersen exon skip-amen dmd
sarepta first day june venu microdystrophin gene therapi data
express would home run
opex continu increas eu launch delay eteplirsen golodirsen casimersen
qtr still limit visibl longer term sale growth driver
ev/ebitda multipl
bottom line rais estim reflect higher sale mainli copaxon
austedo eu line manag revis guidanc rais ep
estim maintain outer year estim larg unchang
manag make good progress drive cost effici struggl get optimist
given uncertainti around fremanezumab launch time remain skeptic inspect
complet next month compet believ less conveni
devic pre-fil syring vs auto-injector pen lilli launch teva
well limit visibl meaning growth driver gener segment reiter
under-perform rate stock
fremanezumab approv expect us eu
austedo sale ramp seem progress well
gener busi perform in-lin expect
full impact gener copaxon come yet continu
believ eros come along
slight increas guidanc sale driven strength us copaxon anda eu fx
restructur initi plan debt pay remain track
busi development/ prioriti time
ep
bottom line result suggest us compani growth acceler trajectori
territori remain intact encourag see rebound organ growth
vs well neotract upsid step-up growth neotract provid believ
posit sustain hsd top-lin growth deliv mid-teen better
ep growth also believ continu upsid potenti above-consensu out-year
forecast consid model contempl meaning benefits/contribut repla
tfx lyophil freeze-dri fresh frozen plasma product develop collabor
 armi medic materi develop activ recent fast track fda
repres increment growth driver neotract sale addt restructur initi
solid ep neotract out-performance perhap importantli qtr org adj sell day
revenue growth y/ mark acceler vs
cc revenue growth guidanc rang reiter op profit upsid get reinvest increment
fx tailwind flow adj ep rang increas
-- analyst day
revenu mm ep present note valuat base pf ep
strong fear pbm biz model overblown sharehold vote posit
ep
bottom line increas convict deep valu invest solid
beat rais quarter despit paus buy-back showcas strong fundament across
board ep beat consensu revenu metric includ cf
solid global supplement busi perform remark top-lin growth margin
expans group steadi ep guidanc rais continu show
impress growth commerci mid-market select segment differenti self-insur
plu stop loss offer expect membership growth acceler cross-sel
financi flexibl medic cost moder offer integr esrx mp product deal
meaning accret well guid admin cost synergi mm excess
 see fear pbm margin compress regulatori chang overblown
even unlik event drug rebat manufactur complet elimin captiv
pbm model add valu medic cost moder align busi model end
payor fear also subsid given challeng logist entrench competit
hospit drug suppli chain link rais ep back
quarter remain consensu expect sharehold vote come week
posit act catalyst expect stock trade deal break close pt remain
strong driven global healthcar global supplement
healthcar metric solid
ep guidanc rais
membership growth commerci middl market select segment continu outperform peer
cross-sel offer acceler growth across combin ci esrx entiti given financi
flexibl afford deal
fear regul pbm margin compress overblown view
much less overhang given decis enter hospit drug suppli chain link
rais ep estim remain consensu
valuat compel view sharehold vote pois posit catalyst
ep exclud item non-gaap ep quarterli number may add total due round
adopt momentum continu drive out-performance runway long
pt
 methodolog ev/sal multipl estim
bottom line morn report strong sale beat rel us street --
vs us vs street -- top-lin growth come consecut quarter
sale growth acceler us impli impella adopt momentum acceler like
driven increas awar around high risk pci expans cardiogen shock initi
nation hospit citi particip continu ramp germani
japan share alreadi meaning print continu recommend
share even current elev level given believ monopoli larg
under-penetrated market give long runway continu top-tier sale growth
progress toward industry-high oper margin like consist estim
upsid acknowledg share cheap feel like chase momentum
buy strongli believ share significantli runway quarterli
result reinforc confid
revenu mm dilut gaap ep
bottom line deliv rev/ep ahead consensu help fx
increas bd new co guidanc rev/ep beat compar organ
growth basic ahead y/i vs us/consensu outlook bd newco includ
bcr impli report revenu guidanc org cc revenue growth y/i
high-end prior org cc revenue growth rang well ep guid
increas vs prior bracket consensu
strong rais end season high note
bottom line deliv strong better expect perform global
healthcar global supplement ep beat consensu revenu
guidanc rais midpoint global healthcar saw margin expans beat
consolid govern commerci sg global supplement also enjoy
consensu top-lin growth margin expans out-performance polici growth across
geographi along premium per life growth also meaning exceed view group disabl
 life larg maintain mid-singl digit margin guidanc rais growth
custom base well govern manag host call edt expect
call focu strong global healthcar fundament medic cost perform growth
select stop loss individu global supplement out-performance sustain margin
expans premium per life growth esrx mp transact synergi anti-trust outlook
bottom line elgx deliv revenue /ep beat vs us/consensu reiter
outlook -- -in good way start year view also conjunct earn
releas compani announc john onopchenko step ceo rein
effect immedi continu think us afx soft weak nellix sale could serv
extend overhang stock least management demonstr progress
front beyond think new ceo appoint could portend improv execut
go forward front monitor year progess -- -at margin view reiter
guidanc downward estim revis sign busi stabil end
day still see elgx catalyst growth re-acceler weight see
rush share reiter mp pt
revenu mm ep adjust item
blend revenu multipl dcf analysi discount rate termin growth
ep loss slightli greater estim driven higher-than-expect
oper expens compani begin pre-commerci activ anticip
lumateperon launch schizophrenia earn releas confirm expect
complet roll nda submiss lumateperon report top-lin data
first bipolar depress studi trade recent week reach
month high march continu see attract risk/reward current level maintain
outperform rate price target updat model recent quarter
d/g mp cyno still overhang nt ep upsid potenti limit pt
 methodolog ep
busi solid pharmedium still weigh
ep
 methodolog ev/ebitda adjust ebitda
recap new ceo lend expertis late-stag development/program
track
outperform market cap price price target methodolog dcf
kol address controversi ahead multipl data readout
on-going delay va weigh result guid reduc
ep
in-lin quarter progress underway growth set acceler
sale multipl sale
solid quarter though invest still weigh outlook
quarter path near-term debt relief pt
pro-forma ebitda leverag
outlook move higher price clariti suggest possibl upsid pt
 methodolog sale
 methodolog ev/ebitda ebitda
medicaid conviva offer strong senior stori could jv
sale
 methodolog price-to-earnings ep
recap pipelin track reiter op
recap track progress ali like launch assum
discount rate termin growth rate
recap biolog stumbl ice recoveri ahead
 rais pois year rais ep pt
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
may genesight data present pharmacogenom test
believ data present american psychiatr associ confer
provid insight secondari genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
scph lead asset furoscix at-hom diuresi anticip pdufa action date
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
sourc leerink research compani inform factset price prior day
fda adcom endocrinolog metabol drug
fda jtn adcom pediatr endocrinolog metabol drug
fda adcom vaccin relat biolog product
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda adcom anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
american societi pediatr hematology/oncolog
intern societi cellular therapi
american societi breast surgeon
american associ immunologist
american associ orthodontist
pan american societi clinic virolog
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
european academi allergi clinic immunolog
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
uk take-over code may make decis respect
potenti bid shire
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo rewind
biopharma -- flash highlight invokana fda warn puls call modest impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt outperform
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
